Cargando…

Operative treatment of cystic prolactinomas: a retrospective study

BACKGROUND: The optimal therapeutic approach for cystic prolactinomas remains unclear. This study aimed to evaluate the remission rates of prolactinoma patients after surgical treatment and the risk factors affecting postoperative remission in cystic prolactinoma patients. METHODS: The clinical data...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Weijie, He, Kejun, Yang, Yibing, Xu, Jiakun, Li, Xixi, Tang, Hongxing, Yang, Jia, Yang, Lixuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157898/ https://www.ncbi.nlm.nih.gov/pubmed/37143054 http://dx.doi.org/10.1186/s12902-023-01343-0

Ejemplares similares

FOXM1 maintains fatty acid homoeostasis through the SET7-H3K4me1-FASN axis
por: Li, Xixi, et al.
Publicado: (2023)

An interesting case of cystic prolactinomas
por: Gopal, Raju A., et al.
Publicado: (2020)

Transsphenoidal surgery for prolactinomas in male patients: a retrospective study
por: Su, Wei-Jie, et al.
Publicado: (2022)

SUN-443 Surgical Management of Cystic Prolactinomas
por: Nevzati, Edin, et al.
Publicado: (2019)

Treatment of Prolactinoma
por: Inder, Warrick J., et al.
Publicado: (2022)

Psychological Health and Sleep Quality of Medical Graduates During the Second Wave of COVID-19 Pandemic in Post-epidemic Era
por: Wu, Honglin, et al.
Publicado: (2022)

Reversal of severe cognitive impairment following medical treatment of cystic invasive giant prolactinoma
por: Bukowczan, J, et al.
Publicado: (2016)

Surgical treatment for male prolactinoma: A retrospective study of 184 cases
por: Song, Yi-Jun, et al.
Publicado: (2017)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
por: Liu, Xiaoshuang, et al.
Publicado: (2019)

Cabergoline Treatment in Invasive Giant Prolactinoma
por: Alsubaie, Sadeem, et al.
Publicado: (2014)

Treatment of Prolactinomas in Low-Income Countries
por: Kruljac, Ivan, et al.
Publicado: (2015)

Experience with Dopamine Agonists in the Treatment of Prolactinomas
por: Barabash, Nadiya Ye., et al.
Publicado: (2022)

Retrospective analysis of 52 patients with prolactinomas following endoscopic endonasal transsphenoidal surgery
por: Han, Yan-Long, et al.
Publicado: (2018)

Approach to the Patient With Prolactinoma
por: Auriemma, Renata S, et al.
Publicado: (2023)

Pituitary Apoplexy during Treatment of Prolactinoma with Cabergoline
por: Ghadirian, Hesam, et al.
Publicado: (2018)

SAT623 Everolimus For Treatment-refractory Prolactinomas
por: Lin, Andrew L, et al.
Publicado: (2023)

Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists
por: Tang, Hao, et al.
Publicado: (2021)

Rapid reduction with cystic transformation of invasive giant prolactinoma following short term low dose cabergoline
por: Dutta, Deep, et al.
Publicado: (2012)

Resistant prolactinoma: Is it monoclonal or polyclonal?
por: Kumar, K. V. S. Hari, et al.
Publicado: (2013)

Managing Prolactinomas during Pregnancy
por: Almalki, Mussa Hussain, et al.
Publicado: (2015)

Serum Survivin Increases in Prolactinoma
por: Dellal, Fatma Dilek, et al.
Publicado: (2015)

Simultaneous Convexity Meningioma and Prolactinoma
por: Figueroa-Angel, Vladimir, et al.
Publicado: (2017)

Current Challenges in the Management of Prolactinomas
por: Maiter, Dominique
Publicado: (2015)

Prolactinomas: evolution after menopause
por: Mallea-Gil, Maria Susana, et al.
Publicado: (2016)

Italian Guidelines for the Management of Prolactinomas
por: Cozzi, Renato, et al.
Publicado: (2023)

Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline
por: Pala, Nazir A., et al.
Publicado: (2015)

Successful treatment of a prolactinoma with the antipsychotic drug aripiprazole
por: Bakker, Ilse C A, et al.
Publicado: (2016)

Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma
por: Hayes, Annabelle G, et al.
Publicado: (2022)

Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?
por: De Sousa, Sunita M C
Publicado: (2022)

Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis
por: Cai, Xiangming, et al.
Publicado: (2022)

Circ‐E‐Cad encodes a protein that promotes the proliferation and migration of gastric cancer via the TGF‐β/Smad/C‐E‐Cad/PI3K/AKT pathway
por: Li, Fanying, et al.
Publicado: (2022)

Altered Connectivity of the Frontoparietal Network During Attention Processing in Prolactinomas
por: Cao, Chenglong, et al.
Publicado: (2021)

Response Activation and Inhibition in Patients With Prolactinomas: An Electrophysiological Study
por: Song, Jian, et al.
Publicado: (2020)

Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists
por: Babey, Muriel, et al.
Publicado: (2010)

Bromocriptine Therapy for the Treatment of Invasive Prolactinoma: The Single Institute Experience
por: Cho, Kyung Rae, et al.
Publicado: (2013)

Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas
por: Schwetz, Verena, et al.
Publicado: (2016)

Cabergoline treatment in prolactinoma: Amelioration in obstructive and central sleep apneas
por: Binar, M, et al.
Publicado: (2019)

Dopamine agonist resistant prolactinomas: any alternative medical treatment?
por: Souteiro, P., et al.
Publicado: (2019)

Abstract 94: Efficacy of cabergoline treatment in men with giant prolactinomas
Publicado: (2022)

Aggressive prolactinomas responsive to temozolomide treatment: Report of two cases
por: Davoudi, Zahra, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qnm12fdk3m9gnv8cj3tknvmotm